Grants Search Results

Louisiana State University Health Sciences Center and Manning Family Children's is committed to improving outcomes during and after cancer treatment. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Children's Hospital of The King's Daughters (CHKD) cares for children diagnosed with cancer in southeast Virginia and northeast North Carolina. Clinical trials at CHKD allow for children throughout their great region to access novel agents without traveling far from home. This grant supports the Clinical Research Team to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Orlando Health Arnold Palmer Hospital for Children's goal is to work towards providing personalized medicine to improve cancer outcomes for children. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports funding towards positions to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The Center for Cancer and Blood Disorders at Phoenix Children's offers early-phase clinical trials for children with cancer, enabling patients to receive the newest, most promising treatments available. This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The UIC/Rush/Stroger Medical Center Children's Oncology Group Program offers pediatric patients the opportunity to enroll onto COG clinical trials, offering cutting edge treatment, optimal care, and comprehensive follow-up. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Golisano Children's Hospital is committed to providing excellent care to all children, adolescents and young adults who are being treated or have been treated with cancer in their region. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Oklahoma Children's has joined the Beat Childhood Cancer Research Consortium, a group of 50+ hospitals that work together to develop new treatments towards treating pediatric cancer. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Medulloblastoma is the most common malignant brain tumor in children. While multimodal therapy for medulloblastoma at diagnosis has resulted in improved outcomes, there are very few options at the time of relapse, with overall poor survival. Preclinical data have shown anti-tumor activity with liothyronine (T3, activated thyroid hormone) in medulloblastoma models. T3 has safety data and dosing which are available for children. Dr. Ronsley and colleagues will translate these preclinical findings into a clinical trial, which will treat children and adolescents with relapsed medulloblastoma with T3 in combination with chemotherapy and evaluate both safety and efficacy and the role for monitoring with liquid biopsy.

This grant is named for Hannah’s Heroes, a Hero Fund established to honor Hannah Meeson. At age 6 she was diagnosed with anaplastic medulloblastoma. After a relapse and additional treatment, Hannah currently shows no evidence of disease. Throughout her treatments, Hannah never complained and remained positive and happy. This fund pays tribute to her fight by raising awareness and funding for all childhood cancers because kids like Hannah “are worth fighting for.”

The most difficult cases of Ewing sarcoma to treat are when it comes back after completing initial treatment. Dr. Brian Ladle and colleagues at Johns Hopkins University and the National Cancer Institute believe the immune system is capable of mounting a powerful immune response against Ewing sarcoma as an effective treatment. Dr. Ladle and team will identify the best immune targets in Ewing sarcoma and discover ways to activate the immune system against the most promising targets. These targets will be tested in their lab using models.

To make a significant impact for kids fighting Ewing sarcoma, five funding partners have banded together with St. Baldrick’s to support this grant – Advancing Cures for Ewing Sarcoma (ACES) award supported by the Sam Day Foundation, The Faris Foundation, Rutledge Cancer Foundation, The Shohet Family Fund for Ewing Sarcoma Research (a St. Baldrick’s Foundation Hero Fund), and Alan B. Slifka Foundation.

Mixed Phenotype Acute Leukemia (MPAL) is a subtype of leukemia that shares features of the 2 most common types of leukemia: acute myeloblastic leukemia and acute lymphoblastic leukemia. Unfortunately, it is really hard to cure with no consensus treatment. When cells divide, chromosomes can break and the pieces can re-attach to the wrong place resulting in a chromosomal translocation. This new abnormal chromosome can result in the expression of a new gene and a new protein, called a "fusion protein". In MPAL, a common translocation involves the ZNF384 gene that can be fused to over 20 new genes, but the consequences are not well understood. Dr Libbrecht has identified that a novel drug that inhibits BRM/BRG1, essential proteins that maintain the DNA structure, and can kill MPAL cells in vitro. Her studies aim to better understand how BRM/BRG1 inhibition affects the ZNF384 fusion proteins and MPAL cells to validate it as novel therapy for MPAL.

Brain tumors are the deadliest type of cancer that afflicts children. The ability of brain tumor cells to spread (metastasize) outside of the original tumor along the leptomeninges, the covering of the brain and spinal cord, is responsible for making many brain tumors so hard to treat. How cancer cells embedded in the leptomeninges survive, thrive, and resist best treatments is poorly understood. A better understanding of leptomeningeal metastasis is required to make new therapies that can meaningfully increase survival for children diagnosed with aggressive brain cancers. Dr. Reinecke and colleagues will create a way that can identify and screen potential therapies in a cell culture dish, thereby streamlining interventions they take to models of pediatric brain tumors. Dr. Reinecke and colleagues believe that establishing this preclinical platform has the potential to identify therapies that have a chance to positively impact the lives of children diagnosed with metastatic brain tumors.

Osteosarcoma is a bone cancer that affects children and adolescents. Unfortunately, its treatment has remained the same since the 1980's, and once the cancer spreads to other organs, less than 40% of the patients survive despite treatment. Dr. Aquino Lopez and colleagues will use the immune system to eliminate tumor cells. During an illness with a virus, immune cells called virus specific T cells (VSTs) eliminate infected cells by recognizing "viral signals". Dr. Aquino Lopez will use an artificial virus combination called CAdVEC to modify cancer cells and make them look like they are infected with a virus. Doing so, will trigger immune cells to eliminate the cancer cells.

Neuroblastoma (NB) is a deadly childhood cancer. Children with NB are classified as high-risk (HR) due to genetics or metastatic disease. Metastatic disease occurs when tumor cells (TC) leave the original tumor and travel to distant organs and develop into new tumors by a complex set of steps. Before tumor cells can form metastasis, they often go through a long period of dormancy (rest) to evade therapy. In NB, the bone marrow is the most common site of metastasis and relapse. The MYCN_TT is a unique model of NB, that spontaneously metastasizes to distant sites such as kidney marrow (equivalent to bone marrow). Dr. Anderson and colleagues will utilize the MYCN_TT model in understanding the molecular and cellular mechanisms underlying metastasis and dormancy, which will inform the development of novel therapeutic strategies for HR-NB.